Stock DNA
Pharmaceuticals & Biotechnology
DKK 15,229 Million ()
13.00
NA
0.00%
-0.16
18.58%
1.16
Revenue and Profits:
Net Sales:
1,653 Million
(Quarterly Results - Jun 2025)
Net Profit:
363 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-19.05%
0%
-19.05%
6 Months
6.35%
0%
6.35%
1 Year
0.03%
0%
0.03%
2 Years
16.06%
0%
16.06%
3 Years
-20.53%
0%
-20.53%
4 Years
-36.35%
0%
-36.35%
5 Years
5.01%
0%
5.01%
Bavarian Nordic A/S for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
29.08%
EBIT Growth (5y)
85.59%
EBIT to Interest (avg)
34.49
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.10
Sales to Capital Employed (avg)
0.35
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.29%
ROCE (avg)
5.55%
ROE (avg)
6.23%
Valuation key factors
Factor
Value
P/E Ratio
13
Industry P/E
Price to Book Value
1.57
EV to EBIT
11.97
EV to EBITDA
8.10
EV to Capital Employed
1.66
EV to Sales
2.68
PEG Ratio
0.15
Dividend Yield
NA
ROCE (Latest)
13.87%
ROE (Latest)
12.29%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bullish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot : Sep 2016
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.29%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
1,653.50
1,350.40
22.45%
Operating Profit (PBDIT) excl Other Income
543.80
423.40
28.44%
Interest
3.30
2.80
17.86%
Exceptional Items
-0.90
-21.10
95.73%
Consolidate Net Profit
362.60
218.80
65.72%
Operating Profit Margin (Excl OI)
225.60%
194.50%
3.11%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 22.45% vs -35.62% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 65.72% vs -71.61% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
5,710.70
7,057.30
-19.08%
Operating Profit (PBDIT) excl Other Income
1,559.20
2,051.30
-23.99%
Interest
13.80
15.00
-8.00%
Exceptional Items
-66.50
-41.30
-61.02%
Consolidate Net Profit
988.00
1,475.20
-33.03%
Operating Profit Margin (Excl OI)
163.60%
212.20%
-4.86%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -19.08% vs 123.98% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -33.03% vs 524.64% in Dec 2023
About Bavarian Nordic A/S 
Bavarian Nordic A/S
Pharmaceuticals & Biotechnology
Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in the development, production and marketing of vaccines for the treatment of cancer and infectious diseases. The Company’s drug pipeline comprises two areas: Cancer Immunotherapy and Infectious Disease. The Cancer Immunotherapy pipeline is focused on: prostate cancer, including PROSTVAC and Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) PRO; breast cancer, providing CV-301 breast and MVA-BN HER2 vaccines; and colorectal cancer, offering CV-301 colon. The Infectious Disease pipeline produces vaccines for a range of illnesses, such as smallpox, anthrax, filoviruses, foot-and-mouth diseases and respiratory syncytial virus. The Company is a parent of Bavarian Nordic GmbH, BN Infectious Diseases A/S, and Bavarian Nordic Inc, among others.
Company Coordinates 
Company Details
Philip Heymans Alle 3 , HELLERUP None : 2900
Registrar Details






